← Back to Screener
Accuray Incorporated (ARAY)
Price$0.46
Favorite Metrics
Price vs S&P 500 (26W)-83.79%
Price vs S&P 500 (4W)3.13%
Market Capitalization$52.79M
All Metrics
P/CF (Annual)18.46x
Book Value / Share (Quarterly)$0.45
P/TBV (Annual)2.15x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)2.17%
Cash Flow / Share (Quarterly)$-0.02
Price vs S&P 500 (YTD)-50.57%
Gross Margin (TTM)27.83%
Net Profit Margin (TTM)-8.15%
EPS (TTM)$-0.30
10-Day Avg Trading Volume1.55M
EPS Excl Extra (TTM)$-0.30
Revenue Growth (5Y)3.67%
EPS (Annual)$-0.02
ROI (Annual)-0.73%
Gross Margin (Annual)32.05%
Net Profit Margin (5Y Avg)-1.75%
Cash / Share (Quarterly)$0.35
Revenue Growth QoQ (YoY)-11.99%
ROA (Last FY)-0.34%
Revenue Growth TTM (YoY)-3.57%
EBITD / Share (TTM)$-0.08
ROE (5Y Avg)-14.58%
Operating Margin (TTM)-3.69%
Cash Flow / Share (Annual)$-0.01
P/B Ratio0.99x
P/B Ratio (Quarterly)1.75x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.34x
Net Interest Coverage (TTM)1.15x
ROA (TTM)-7.66%
EV / EBITDA (TTM)22.35x
EPS Incl Extra (Annual)$-0.02
Current Ratio (Annual)1.65x
Quick Ratio (Quarterly)0.64x
3-Month Avg Trading Volume1.21M
52-Week Price Return-69.75%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.31
P/S Ratio (Annual)0.12x
Asset Turnover (Annual)0.97x
52-Week High$2.10
Operating Margin (5Y Avg)1.53%
EPS Excl Extra (Annual)$-0.02
CapEx CAGR (5Y)2.75%
Tangible BV CAGR (5Y)0.83%
26-Week Price Return-75.05%
Quick Ratio (Annual)0.85x
13-Week Price Return-47.47%
Total Debt / Equity (Annual)1.68x
Current Ratio (Quarterly)1.47x
Enterprise Value$147.385
Revenue / Share Growth (5Y)1.09%
Asset Turnover (TTM)0.94x
Book Value / Share Growth (5Y)0.66%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.23x
Pretax Margin (Annual)0.25%
Cash / Share (Annual)$0.51
3-Month Return Std Dev101.52%
Gross Margin (5Y Avg)35.20%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)-6.42%
ROE (Last FY)-1.96%
Net Interest Coverage (Annual)-0.97x
EPS Basic Excl Extra (Annual)$-0.02
P/FCF (TTM)1.87x
Receivables Turnover (TTM)5.82x
EV / Free Cash Flow (TTM)9.50x
Total Debt / Equity (Quarterly)2.54x
EPS Incl Extra (TTM)$-0.30
Receivables Turnover (Annual)5.18x
ROI (TTM)-17.12%
P/S Ratio (TTM)0.12x
Pretax Margin (5Y Avg)-1.11%
Revenue / Share (Annual)$4.46
Tangible BV / Share (Annual)$0.58
Price vs S&P 500 (52W)-104.84%
Year-to-Date Return-46.43%
5-Day Price Return5.17%
EPS Normalized (Annual)$-0.02
ROA (5Y Avg)-1.61%
Net Profit Margin (Annual)-0.35%
Month-to-Date Return13.81%
Cash Flow / Share (TTM)$-0.02
EBITD / Share (Annual)$0.15
Operating Margin (Annual)2.03%
LT Debt / Equity (Annual)1.52x
P/CF (TTM)11.61x
ROI (5Y Avg)-3.36%
LT Debt / Equity (Quarterly)2.34x
EPS Basic Excl Extra (TTM)$-0.30
P/TBV (Quarterly)2.57x
P/B Ratio (Annual)1.74x
Inventory Turnover (TTM)2.10x
Pretax Margin (TTM)-7.59%
Book Value / Share (Annual)$0.72
Price vs S&P 500 (13W)-50.34%
Beta1.39x
P/FCF (Annual)18.46x
Revenue / Share (TTM)$3.61
ROE (TTM)-57.91%
52-Week Low$0.33
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.38
4.38
4.38
4.38
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
ARAYAccuray Incorporated | 0.12x | 3.67% | 27.83% | -3.69% | $0.46 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Accuray manufactures the CyberKnife, a precision radiation oncology system for treating cancers and tumors throughout the body. The system automatically detects and corrects for tumor and patient movement in real-time, delivering high-dose radiation with sub-millimeter accuracy while patients breathe normally and without requiring manual intervention. This technology sets the standard for precision radiation therapy in cancer treatment.